PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
| Recruiting | 1 | 75 | US | FX-909 | Flare Therapeutics Inc. | Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label | 09/26 | 01/27 | | |
